VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

SARS-CoV Ad S/N vaccine
Vaccine Information
  • Vaccine Name: SARS-CoV Ad S/N vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein, N (See et al., 2006)
  • S protein gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • N gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: intranasal immunization
  • Description: A combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (See et al., 2006)
Host Response

Mouse Response

  • Vaccination Protocol: Mouse was immunized on day 0 and week 4 (See et al., 2006)
  • Immune Response: Quantifiable humoral response with presence of SARS-CoV-specific IgG1 and a significant reduction in level of SARS-CoV RNA in lung titers(See et al., 2006)
  • Challenge Protocol: Mouse was immunized on day 0 and week 4 and then challenged with SARS-COV Tor2 at week 7 (See et al., 2006).
References
See et al., 2006: See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. The Journal of general virology. 2006; 87(Pt 3); 641-650. [PubMed: 16476986].